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Abstract
Background: Synthetic and natural antioxidants including Bacopa monnieri (L.) Pennell (Scrophulariaceae) which
also possess anti-dopaminergic properties, have been proposed to be useful for emetogenic chemotherapy. In this
study, synthetic [N-(2-mercaptopropionyl) glycine (MPG), vitamin C (Vit-C)] and natural [grape seed proanthocyanidin
(GP), B. monnieri n-butanolic fraction (BM-ButFr)] antioxidants and their combinations were evaluated against
cisplatin-induced emesis in pigeons during a 24 h observation period.
Methods: Emesis was induced using cisplatin (7.0 mg/kg, i.v). MPG (10, 20, 30 mg/kg), Vit-C (100, 200, 300 mg/kg),
GP (50, 100, 150 mg/kg) and BM-ButFr (5, 10, 20 mg/kg) and their combinations were administered i.m., 15 min before
cisplatin administration. The number of vomiting bouts, retching, emetic latency and % weight loss were recorded to
assess antiemetic potential. Antioxidant activity was evaluated by the DPPH free radical scavenging assay (FRSA).
Results: Significant attenuation of vomiting bouts, retching, % weight loss along with an increase in latency was
produced by all the antioxidants and their combinations compared to cisplatin alone and this is the first report of this
activity of GP in pigeons. Low EC50 values in the FRSA for MPG (67.66 μg/mL), Vit-C (69.42 μg/mL), GP (6.498 μg/mL)
and BM-ButFr (55.61 μg/mL) compared to BHT standard (98.17 μg/mL) demonstrated their radical scavenging capacity.
Correlation between the antioxidant activity and antiemetic efficacy disclosed a high degree of correlation for the
tested antioxidants.
Conclusion: The selected synthetic and natural antioxidants and their combinations were able to attenuate
cisplatin-induced vomiting, which correlated with their potent in vitro antioxidant activity.
Keywords: Emesis, Antiemetic, Chemotherapy, Bacopa monnieri, Grape seed proanthocyanidin, N-(2-mercaptopropionyl)
glycine, Vitamin C, Free radical scavenging assay, Correlation
Background
Nausea and vomiting are the most distressing and com-
monly occurring side effects of chemotherapeutic agents
[1]. Indeed, chemotherapy can induce both acute and
delayed phases of nausea and vomiting [2]. In pigeons
and piglets for instance, the acute phase lasts for 8–16 h
while the delayed phase may endure for 48–58 h [3].
However, in humans, the acute and delayed phases per-
sist for 24 and 7 days, respectively [4]. The mechanisms
underlying emesis have been investigated in carnivores
such as ferrets, dogs [5], and cats [6], insectivores like
Suncus murinus (musk shrew) [7] and Cryptotis parva
(least shrew) (Soricidae) [8, 9]. Similarly, birds, notably
pigeons, also display clear-cut emetic responses to
copper sulphate, glucagon, digoxin [10], theophylline
[11] and amantadine [12].
Cisplatin is an effective chemotherapeutic agent indi-
cated for the management of different malignancies in-
cluding ovarian [13], head and neck [14], testicular and
bladder carcinomas [15]. Its use is associated with
many side effects, of which vomiting is distinctly the
most distressing [16]. It decreases the plasma levels of
various antioxidants [17] and also generates both oxida-
tive and nitrosative stress [18, 19]. The oxidative stress
component plays a significant role in cisplatin-induced
side effects as well as various other complications [20].
Antioxidants are effective in reducing oxidative stress
evoked by cisplatin [21] and they play a pivotal role in
protecting against cisplatin elicited nephrotoxicity [22],
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hepatotoxicity [23] and ototoxicity [24]. A range of anti-
oxidants including vitamin C, N-2-mercaptopropionyl
glycine (MPG, also named tiopronin), glutathione and
vitamin E are known to be effective in cisplatin emeto-
genesis [25]. In this context, the synthetic antioxidant
MPG, reduces cisplatin and pyrogallol provoked vomit-
ing in Suncus murinus [26]. Proanthocyanidin (GP) an
antioxidant flavonoid [27], not only possesses neuropro-
tective activity in humans [28] and animals [29], but also
initiates a reduction of pica behavior (eating of non-food
substances as a model of simulated emesis) in rats [30].
Additionally, it is effective against cisplatin-induced
nephrotoxicity and hepatotoxicity [31, 32], provides car-
dioprotection and enhances cognitive performance [33].
Similarly, Bacopa monnieri (L.) Pennell (Scrophularia-
ceae), a reputed nootropic plant and a rich source of
bacosides has strong antioxidant [34] and neuroprotec-
tive properties [35].
Although previous studies advocate the effectiveness
of antioxidants as antiemetics [25, 36], there is no report
available in the literature showing any direct correlation
between antiemetic propensity and antioxidant activity
in the pigeon model for emetogenesis. The aim of this
study therefore was threefold: firstly to determine any
antiemetic activity of selected natural and synthetic anti-
oxidants either alone or in combination. Secondly to
evaluate their antioxidant potential and thirdly, to estab-
lish any possible correlation between their antioxidant
and antiemetic activities.
Methods
Animals
Pigeons of either sex (mix breed, Department of Pharmacy,
University of Peshawar, Pakistan) weighing between 200–
400 g were used. They were acclimatized 24 h before the
start of the experiment and were maintained at 22–26 °C
on a 12 h light-dark cycle. Food and water were provided
ad libitum. The experiments were performed in accord-
ance with the UK Animals (Scientific Procedures) Act
1986 and were approved by the Ethical Committee of the
Department of Pharmacy, University of Peshawar (Refer-
ence No. 14/EC-12/Pharm).
Chemicals and standards
Cisplatin (Korea United Pharm. Inc. Korea), analytical
grade methanol (Sigma-Aldrich, Switzerland), 2,2-diphe-
nyl-1-picrylhydrazyl (DPPH; Sigma-Aldrich, Germany),
vitamin C (Vit-C; Sigma-Aldrich, Germany), butylated
hydroxytoluene (BHT; Sigma-Aldrich, Germany), grape
seed proanthocyanidin extracts (GP; Shaanxi Run-time
Biotechnology Development Co. Ltd, Xian, China), N-(2-
mercaptopropionyl) glycine (MPG; Sigma-Aldrich,
Germany), metoclopramide (GlaxoSmithKline).
Preparation of n-butanolic fraction of B. monnieri extract
Whole plant of B. monnieri was collected in November,
2010 from Rumalee stream near Quaid-e-Azam University,
Islamabad, Pakistan. It was authenticated by Prof. Dr.
Muhammad Ibrar of the Department of Botany, University
of Peshawar and a specimen was deposited in the herbar-
ium of the same Department with a voucher No 7421. The
aerial parts were separated, shade dried and coarsely pow-
dered. They were extracted with methanol in a Soxhlet ap-
paratus and further fractionated to obtain the n-butanolic
fraction (BM-ButFr) which is reported to be rich in baco-
sides [37]. Bacosides are the major active constituents of B.
monnieri and they are considered to be responsible for its
myriad pharmacological properties [38].
Antiemetic activity
Preparation of drug solutions
Cisplatin was dissolved in saline at 65–75 °C with continu-
ous shaking and was cooled before administration. GP,
MPG, Vit-C and BM-ButFr were dissolved in sterile nor-
mal saline by gentle agitation and sonicated until uniform
solutions were obtained. These solutions were then imme-
diately administered by the intramuscular route (i.m.).
Induction of emesis
The maximal (100%) emetic dose of cisplatin (7.0 mg/kg)
was used as an emetic challenge [39]. It was administered
intravenously via the brachial vein and pigeon behavior
was recorded for 24 h by video recorder. Any response
with or without oral expulsion of gastric contents was
considered as one bout (vomiting episode) and if occur-
ring after a gap of 1 min from another bout, they were
considered as separate vomiting episodes with 2 up to 80
numbers of retching (emetic behaviors) [40]. The latency
to first vomit, the number of bouts, retching and % weight
loss were all recorded.
Drug treatment
Emesis was induced by administering cisplatin
(7.0 mg/kg) intravenously. MPG, Vit-C, GP and BM-
ButFr or their combination as well as metoclopramide
used as the standard antiemetic agent, were adminis-
tered as pretreatments 15 min i.m. prior to cisplatin
administration. The different doses of the tested com-
pounds were selected according to previous studies
[25, 39, 41, 42]. The animals were divided into the
following groups:
Group I: Cisplatin control (7.0 mg/kg), n = 8.
Group II: Metoclopramide (30 mg/kg), n = 8.
Group III: MPG (10, 20, and 30 mg/kg), n = 8 each
per dose.
Group IV: Vit-C (100, 200, and 300 mg/kg), n = 8 each
per dose.
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Group V: GP (50, 100, and 150 mg/kg), n = 8 each
per dose.
Group VI: BM-ButFr (5, 10, and 20 mg/kg), n = 8 each
per dose.
Group VII: Combination of MPG (10 mg/kg) plus
Vit-C (200 mg/kg), n = 7.
Group VIII: Combination of BM-ButFr (10 mg/kg) plus
GP (100 mg/kg), n = 8.
Group IX: Combination of GP (100 mg/kg) plus Vit-C
(200 mg/kg), n = 8.
The percentage reduction in the frequency of cisplatin-
induced vomiting bouts was calculated as:
% Reduction ¼ ð1 – mean number of bouts after treatment
mean number of bouts of untreated controlÞ
 100
DPPH (2,2-diphenyl-1-picrylhydrazyl) free radical
scavenging activity in vitro
The antioxidant activities of MPG, Vit-C, GP and BM-
ButFr were evaluated by the DPPH free radical scavenging
assay [43, 44]. Briefly, 2.0 mL of methanolic 0.1 mM
DPPH free radical solution was added to 1.0 mL of differ-
ent concentrations (1.0, 10, 30, 50, 100, 200, 500 μg/mL)
of GP, MPG, Vit-C, BM-ButFr or standard (BHT: butyl-
ated hydroxytoluene) in methanol. The solutions were
shaken thoroughly, incubated in the dark at ambient
temperature for 30 min and absorbance was measured at
517 nm using a UV/Visible spectrophotometer (Lambda
25, PerkinElmer, USA). The % scavenging of DPPH free
radicals was calculated as follows:
% of DPPH free radical scavenging activity
¼ AI‐AII=A1ð Þ  100½ 
Where AI is the absorbance of the control reaction
and AII is the absorbance in the presence of sample.
The EC50, defined as the concentration of antioxidant
causing 50% loss of DPPH activity was calculated from
the graph of absorbance versus respective concentrations
using non-linear regression analysis. All experiments
were performed in triplicate.
Statistical analysis
Data were expressed as mean ± S.E.M (n = 7–8) and ana-
lyzed by one way ANOVA followed by Tukey’s multiple
comparison using GraphPad Prism 5 (GraphPad Soft-
ware Inc. San Diego CA, USA). Correlation analysis of
antioxidant activity versus antiemetic activity of each
antioxidant was carried out using the Pearson’s correl-
ation and regression program in Minitab version 17.1.0
(Minitab Inc. State College, PA 16801 USA).
Results
Antiemetic activity of N-(2-mercaptopropionyl) glycine
(MPG), vitamin C (Vit-C), grape seed proanthocyanidin (GP),
and B. monnieri n-butanolic fraction (BM-ButFr) as well as
MPG + Vit-C, BM-ButFr + GP and GP + Vit-C combinations
As shown in Fig. 1, cisplatin generated a consistently main-
tained number of vomiting bouts over a 24 h period. It also
induced retching; weight loss (%) and a decreased latency
to first vomit (Table 1). Highly significant reductions in the
number of bouts were found with MPG [F (3,28) = 10.62,
P < 0.0001] (10, 20 mg/kg; 0–8 h, P < 0.001) (Fig. 2a), Vit-C
[F (3,28) = 9.985, P = 0.0001] (100–300 mg/kg; 0–4 h,
P < 0.001) (Fig. 2b), GP [F (3,28) = 50.97, P < 0.0001]
(50–150 mg/kg; 0–8 h, P < 0.001) (Fig. 2c) and BM-
ButFr [F (3,28) = 48.28, P < 0.0001] (5–20 mg/kg; 0–8 h
and 13–16 h, P < 0.001) (Fig. 2d). However, the reductions
were less significant (P < 0.01) for MPG at 30 mg/kg
(0–4 h; Fig. 2a), Vit-C at 200 mg/kg (5–8 h; Fig. 2b),
GP at 150 mg/kg (13–24 h; Fig. 2c) and BM-ButFr at
5–20 mg/kg (17–20 h; Fig. 2d) as compared to the cis-
platin control. In the case of the combinations [F (3,27) =
33.55, P < 0.0001], highly significant inhibition (P < 0.001)
of vomiting bouts was observed up to 4 h after cisplatin
Fig. 1 Cisplatin (7.0 mg/kg i.v) induced vomiting bouts in pigeons during a 24 h observation period. Each bar represents mean ± S.E.M (n = 8)
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administration. The GP (100 mg/kg) + Vit-C (200 mg/kg)
combination maintained marked significance at 5–8 h and
during 17–20 h (P < 0.001) whilst the other two combina-
tions had fluctuating inhibitory activity of low statistical
significance (see Fig. 2e).
A 100% reduction in the frequency of cisplatin-
induced vomiting bouts was observed with GP (100
and 150 mg/kg) and Vit-C (300 mg/kg). Adequate
protection was also produced by MPG at 10 mg/kg
(72–94%), 20 mg/kg (66–83%) and 30 mg/kg (35–60%);
Vit-C at 100 mg/kg (28–78%) and 200 mg/kg (49–77%);
GP at 50 mg/kg (63–97%) and BM-ButFr at 5 mg/kg
(49–79%), 10 mg/kg (61–78%) and 20 mg/kg (67–84%)
during the acute phase (0–12 h) of cisplatin-induced
vomiting. Likewise, during the delayed phase (13–24 h),
the antiemetic propensity was observed as 47–60%
(10 mg/kg), 0–70% (20 mg/kg) and 3–49% (30 mg/kg) for
MPG; 0–35% (100 mg/kg), 6–36% (200 mg/kg) and 8–
35% (300 mg/kg) for Vit-C; 41–59% (50 mg/kg), 57–68%
(100 mg/kg) and 73–88% (150 mg/kg) for GP and 65–74%
(5 mg/kg), 57–70% (10 mg/kg) and 61–69% (20 mg/kg)
for BM-ButFr. A highly effective percentage reduction of
cisplatin-induced vomiting was afforded by the combina-
tions of MPG (10 mg/kg) + Vit-C (200 mg/kg), BM-ButFr
(10 mg/kg) + GP (100 mg/kg) and GP (100 mg/kg) + Vit-C
(200 mg/kg) as 72–83%, 53–86% and 54–85% during the
acute phase and 62–75%, 53–60% and 84–92% during the
delayed phase, respectively (see Additional file 1).
Extremely significant reductions in the number of
retching episodes was noted for MPG [F (3,27) = 6.639,
P = 0.0016] (10 mg/kg, P < 0.001), Vit-C [F (3,28) =
9.658, P = 0.0002] (300 mg/kg, P < 0.001) and GP [F
(3,28) = 12.70, P < 0.0001] (100, 150 mg/kg, P < 0.001)
while less significant decrements were observed with
MPG at 20 mg/kg (P < 0.05), Vit-C at 100 mg/kg (P < 0.05)
and 200 mg/kg (P < 0.01), GP at 50 mg/kg (P < 0.01)
and BM-ButFr [F (3,28) = 4.799, P = 0.0080] at 20 mg/
kg (P < 0.01). Moreover, the reductions in the % weight
loss were very significant with BM-ButFr [F (3,28) = 10.12,
P = 0.0001] at 10, 20 mg/kg (P < 0.001), GP [F (3,28) =
18.03, P < 0.0001] and Vit-C [F (3,28) = 20.98, P < 0.0001]
at all tested doses (P < 0.001). However, the decreases were
less significant for MPG [F (3,28) = 4.938, P = 0.0071] at
10 mg/kg (P < 0.01), 20 mg/kg (P < 0.05) and 30 mg/kg
(P < 0.05) and with BM-ButFr at 5 mg/kg (P < 0.01).
Furthermore, significant increases in vomiting latency
were observed with GP [F (3,28) = 23.93, P < 0.0001] at
all doses (P < 0.001) but the increases were less signifi-
cant for MPG [F (3,28) = 4.170, P = 0.0146] (10 mg/kg,
P < 0.05) and Vit-C [F (3,28) = 5.048, P = 0.0064] (200,
300 mg/kg, P < 0.05) (Table 1). A tendency towards an
increase in vomiting latency was observed with BM-
ButFr [F (3,28) = 2.449, P = 0.084] at all doses. In the
positive control group, metoclopramide (30 mg/kg) sig-
nificantly alleviated (P < 0.001) cisplatin-induced vomit-
ing bouts, retching and percentage weight loss, while it
Table 1 Activity of N-(2-mercaptopropionyl) glycine (MPG), vitamin C (Vit-C), grape seed proanthocyanidin (GP), B. monnieri
n-butanolic fraction (BM-ButFr) and their combination against cisplatin induced vomiting during a 24 h observation period
Treatment Dose and route Pigeons tested/vomited Bouts Latency (min) Retching Wt. loss (%)
Cisplatin 7.0 mg/kg i.v. 8/8 50 ± 3.2 70.0 ± 2.30 561 ± 56.4 16 ± 1.8
Metoclopramide 30 mg/kg i.m. 8/8 8 ± 0.8*** 417 ± 7.00*** 134 ± 12.5*** 4 ± 0.6***
MPG 10 mg/kg i.m. 8/6 12 ± 5.8*** 410 ± 162* 135 + 55.6*** 4 ± 1.9**
20 mg/kg i.m. 8/7 21 ± 4.9** 91.0 ± 11.5 226 + 80.9* 7 ± 1.2*
30 mg/kg i.m. 8/7 23 ± 5.6** 89.0 ± 21.1 329 + 79.2 7 ± 3.2*
Vit-C 100 mg/kg i.m. 8/8 30 ± 3.2** 146 ± 16.7 384 ± 23.5* 7 ± 1.3***
200 mg/kg i.m. 8/8 24 ± 4.6*** 316 ± 96.2* 332 ± 52.4** 5 ± 1.1***
300 mg/kg i.m. 8/8 24 ± 3.0*** 359 ± 73.2* 256 ± 21.0*** 3 ± 0.5***
GP 50 mg/kg i.m. 8/8 14 ± 3.5*** 348 ± 42.5*** 236 ± 78.9** 6 ± 0.8***
100 mg/kg i.m. 8/8 12 ± 2.2*** 370 ± 31.6*** 184 ± 37.0*** 6 ± 1.0***
150 mg/kg i.m. 8/8 9.0 ± 0.9*** 369 ± 27.8*** 139 ± 27.2*** 5 ± 0.5***
BM-ButFr 5 mg/kg i.m. 8/8 17 ± 2.6*** 161 ± 25.0 331 ± 74.0 7 ± 0.5**
10 mg/kg i.m. 8/8 15 ± 2.1*** 145 ± 36.0 378 ± 58.0 6 ± 1.4***
20 mg/kg i.m. 8/8 13 ± 1.7*** 137 ± 25.0 253 ± 45.0** 5 ± 1.7***
Combination
MPG + Vit-C 10 mg/kg + 200 mg/kg i.m. 7/7 12 ± 4.7*** 421 ± 134* 201 ± 68.2*** 3 ± 1.1***
BM-ButFr + GP 10 mg/kg + 100 mg i.m. 8/8 17 ± 0.9*** 195 ± 24.1 196 ± 16.3*** 5 ± 0.2***
GP + Vit-C 100 mg/kg + 200 mg/kg i.m. 8/8 9.0 ± 3.3*** 309 ± 90.6 166 ± 61.3*** 3 ± 0.9***
Values are expressed as mean ± S.E.M. *P < 0.05, **P < 0.01, ***P < 0.001 compared to cisplatin control (ANOVA followed by Tukey’s post hoc analysis)
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significantly increased (P < 0.001) the latency to vomit-
ing during the entire observation period.
The number of vomiting bouts, retching [F (3,27) =
12.54, P < 0.0001] and % weight loss [F (3,26) = 25.72,
P < 0.0001] were significantly reduced (P < 0.001) by
all the combinations of selected antioxidants when com-
pared to the cisplatin control. In addition, the vomiting
latency [F (3,27) = 3.710, P = 0.0235] was significantly
increased (P < 0.05) by the combination of MPG
(10 mg/kg) + Vit-C (200 mg/kg) (Table 1).
The global reduction in the number of emetic bouts
for the selected antioxidants and their combinations de-
creased in the following respective rank orders: GP >
BM-ButFr >MPG > Vit-C and GP + Vit-C >MPG +Vit-
C > BM-ButFr + GP.
In vitro antioxidant activity of N-(2-mercaptopropionyl)
glycine (MPG), vitamin C (Vit-C), grape seed
proanthocyanidin (GP) and B. monnieri n-butanolic
fraction (BM-ButFr)
The maximum inhibition of DPPH free radicals by BHT
(standard) was 93.82% at 500 μg/mL while those of
MPG, Vit-C, GP and BM-ButFr were 96.15% at 200 μg/
mL, 96.71% at 500 μg/mL, 92.42% at 50 μg/mL and
90.94% at 100 μg/mL respectively as shown in Table 2.
MPG, Vit-C, GP and BM-ButFr or standard (BHT)
Fig. 2 Antiemetic effect of N-(2-mercaptopropionyl) glycine (MPG), vitamin C (Vit-C), grape seed proanthocyanidin (GP), and B. monnieri
n-butanolic fraction (BM-ButFr). a MPG (10, 20, 30 mg/kg); b Vit-C (100, 200, 300 mg/kg); c GP (50, 100, 150 mg/kg); d BM-ButFr (5, 10,
20 mg/kg) and e their combinations on cisplatin (7 mg/kg) induced vomiting during a 24 h observation period. Each bar represents
mean ± S.E.M (n = 7–8). *p < 0.05, **p < 0.01 ***p < 0.001 compared to cisplatin control (ANOVA followed by Tukey’s post hoc analysis)
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exhibited concentration dependent declines in spectral ab-
sorbance (Fig. 3). The EC50, antiradical power and stoichi-
ometry of MPG, Vit-C, GP, BM-ButFr and BHTare shown
in Table 2 and the antioxidant activity, established by EC50
values was decreased in the following rank order: GP >
BM-ButFr >MPG >Vit-C > BHT.
Correlations between in vitro antioxidant and in vivo
antiemetic activities
The antiemetic activities in vivo were correlated with the
free radical scavenging capacities of the natural and syn-
thetic antioxidants in vitro. Figure 4 shows the high degree
of Pearson correlation between the number of vomiting
bouts and the % of maximum free radical scavenging cap-
acity of the selected antioxidants. The results manifested
positive correlation coefficients for MPG (r = 0.9690),
GP (r = 0.9926) and BM-ButFr (r = 0.9635). However,
a negative correlation coefficient between the number
of bouts and antioxidant activity was observed with
Vit-C (r = − 0.9838). The coefficients of determination
(R2: a statistical measure of how well the regression
lines represent the data), disclosed an association be-
tween antioxidant activity and antiemetic assay out-
come. This deduction was substantiated by the values
obtained for MPG (R2 = 0.9390), Vit-C (R2 = 0.9680),
GP (R2 = 0.9853) and BM-ButFr (R2 = 0.9283) (Fig. 4).
Discussion
In this study, different antioxidants of natural and syn-
thetic origin were evaluated for their antiemetic activity
against cisplatin-induced retching and vomiting in pi-
geons. In emetogenesis studies, different animal models
including monkeys [45], pigs [46], ferrets [47], dogs [48],
cats [49], house musk shrews [50] and rats [51] have
been utilized for evaluating antiemetic compound activity.
However, these models have some limitations in terms of
cost, ease of handling, absence of a vomiting center, and
inability to vomit. We have chosen the pigeon emesis
model due to the fact that it expresses readily quantifiable
vomiting response parameters as reported in previous
studies [3, 52]. The pigeon responds to a number of differ-
ent emetic stimuli, including cardiac glycosides [53], reser-
pine [54], sigma receptor ligands [55], 5-HT3 receptor
agonists [56] and chemotherapeutic drugs [57]. The
pigeon model can also be used to assay the antiemetic ac-
tivity of several classes of drugs for example NK1 receptor
antagonists [58] and glucocorticoids [59].
Vomiting induced by cisplatin is biphasic with an acute
phase lasting for 24 h and a delayed phase extending to
several days [2]. In pigeons, there is no mechanistically
distinct acute or delayed phase of chemotherapy-induced
vomiting, although earlier studies have monitored emesis
for up to 72 h [59]. In our investigation, we observed the
animals for 24 h in order to comply with the ethical use of
animals. The dose of cisplatin for induction of emesis var-
ies with the animal model [45, 60, 61]. We utilized cis-
platin at a dose of 7.0 mg/kg for pigeons [39] and
observed a robust elevation in the number of vomiting
bouts, retching and % weight loss after 24 h.
Cancer chemotherapy is associated with generation of
reactive oxygen species [62] and oxidative stress has
been implicated in the emesis caused not only by cis-
platin but other chemotherapeutic drugs as well [63].
Numerous studies have shown that the active metabolite
of cisplatin i.e. cis-diaqodiammineplatinum generates
free radicals that release serotonin from enterochromafin
cells which then stimulate 5-HT3 receptors on vagal af-
ferents and initiate the emetic reflex within the brain
Table 2 Percent of DPPH free radical scavenging activity and antioxidant strength of A-(2-mercaptopropionyl) glycine (MPG),
vitamin C (Vit- C), grape seed proanthocyanidin (GP), B. monnieri n-butanolic fraction (BM-ButFr) or standard butylated
hydroxytoluene (BHT) against their respective concentrations
Concentration (μg/mL) Percent inhibition (%)
BHT MPG Vit-C GP BM-ButFr
1 15.0 ± 0.7 20.0 ± 2.1 14.6 ± 1.5 36.4 ± 0.8 24.5 ± 0.7
10 24.4 ± 4.2 20.8 ± 1.8 15.7 ± 0.6 71.6 ± 0.7 20.9 ± 0.8
30 22.1 ± 1.4 19.4 ± 1.2 17.3 ± 1.5 82.6 ± 1.2 32.2 ± 2.4
50 22.8 ± 0.5 24.4 ± 1.0 21.2 ± 2.4 92.4 ± 0.1 46.5 ± 2.9
100 58.6 ± 3.8 94.0 ± 0.01 92.7 ± 0.7 92.4 ± 0.2 90.9 ± 0.5
200 89.7 ± 2.4 96.2 ± 0.2 96.0 ± 0.3 91.6 ± 0.3 90.7 ± 0.3
500 93.8 ± 0.1 96.0 ± 0.7 96.7 ± 0.2 89.6 ± 0.2 89.9 ± 0.4
Antioxidant strength
EC50 (μg/mL) 98.17 ± 3.842 67.66 ± 3.095 69.42 ± 3.027 6.498 ± 0.630 55.61 ± 1.137
Antiradical power 0.0102 ± 0.0004 0.0148 ± 0.0007 0.0143 ± 0.0005 0.1567 ± 0.0145 0.0159 ± 0.0010
Stoichiometry 196.3 ± 7.685 135.3 ± 6.191 138.8 ± 6.053 13.00 ± 1.261 111.2 ± 2.274
Values are expressed as mean ± S.E.M from three separate experiments
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stem [64, 65]. Since the emetogenic effect of cisplatin is
associated with the generation of reactive oxygen species
(ROS), administration of antioxidants could detoxify
ROS and thereby prevent cisplatin-induced emesis. Ac-
cordingly, antioxidants and free radical scavengers have
been shown to increase the therapeutic efficacy of
chemotherapy by improving tolerance and reducing their
dose limiting toxicities [66]. In the present study, we have
examined well established synthetic and natural antioxi-
dants, including MPG, Vit-C, GP and BM-ButFr. More-
over, the doses chosen for these antioxidants were tolerable
and benign based on their toxicity profiles [67–70].
All the selected antioxidants at the doses tested signifi-
cantly decreased the number of vomiting bouts, retching
and % weight loss whilst at the same time, increasing the
latency to vomiting. The most intense antiemetic effect
was observed with GP followed by BM-ButFr, MPG then
Vit-C and our study is the first to report the antiemetic ac-
tivity of GP in the pigeon vomit model. GP at doses of 100
and 150 mg/kg produced a complete reversal of emesis as
seen by a 100% reduction in the frequency of cisplatin-
induced vomiting bouts. Previously, GP at 10 mg/kg has
been shown to produce a significant reduction of cisplatin-
induced pica behavior in rats and this is exemplified by a
decreased kaolin intake [30], which is regarded as being
analogous to emesis [51]. Proanthocyanidin, at 200 mg/kg,
ameliorated the cisplatin-induced decrease in the activities
of antioxidant enzymes, GSH, total protein and albumin
[31] while at 250 mg/kg, it alleviated cisplatin-induced hep-
atotoxicity in rabbits by reducing ROS generation and
strengthening endogenous antioxidant systems [32]. It is
noteworthy that in rodents, investigations employing a
similar dose of grape seed proanthocyanidin as that used in
our study, reported beneficial effects which have been
Fig. 4 Linear correlation showing the involvement of in vitro antioxidant activities of N-(2-mercaptopropionyl) glycine (MPG), vitamin C (Vit-C),
grape seed proanthocyanidin (GP) and B. monnieri n-butanolic fraction (BM-ButFr) in the reduction of cisplatin induced vomiting bouts in pigeons
Fig. 3 DPPH free radical scavenging assay in vitro showing absorbance
of N-(2-mercaptopropionyl) glycine (MPG), vitamin C (Vit-C), grape seed
proanthocyanidin (GP), B. monnieri n-butanolic fraction (BM-ButFr)
or standard (butylated hydroxytoluene: BHT) against their respective
concentrations. Data are presented as mean ± SD of three
separate experiments
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attributed to an ability to support the antioxidant defense
system [41, 71].
Different plants have been screened against cisplatin-
induced emesis in a variety of animal models. These
include Zingiber officinale Rosc. (Zingiberaceae) [48], Scu-
tellaria baicalensis Georgi (Lamiaceae) [72] and American
ginseng berry (Panax quinquefolius L.) (Araliaceae) [73].
In these studies, the antiemetic effect has been attributed
to the free radical scavenging property and an antiseroto-
nergic action of the different active constituents. In the
current investigation, the n-butanolic fraction of B. mon-
nieri (BM-ButFr) exhibited a dose dependant antiemetic
activity and this accords with our previous report in which
BM-ButFr significantly reduced cisplatin-induced emeto-
genesis [39]. The superior antiemetic effect of BM-ButFr
compared to the synthetic antioxidants seen here, may be
ascribed to the presence of bacoside-A components,
which along with bacopaside I, constitute more than 96%
w/w of the total saponins present in the extract [74]. How-
ever, the antiemetic activity of B. monnieri may also be
mediated through other mechanisms in addition to its
antioxidant activity [75] because B. monnieri has both
anti-dopaminergic and anti-serotonergic properties [76].
In relation to this, serotonin [77] and dopamine [78] both
play an important role in the induction of vomiting at the
level of the area postrema. However, serotonin has been
shown to differentially mediate the early emetic phase fol-
lowing cisplatin treatment [77]. In line with this, our pre-
vious study showed that B. monnieri not only attenuated
the cisplatin-induced dopamine upsurge in the area post-
rema and brain stem but it also diminished the intestinal
serotonin concentration in the pigeons [39].
MPG is a well-known synthetic aminothiol antioxidant
that has been studied widely especially for its cardiopro-
tective properties [78, 79]. In the present pigeon emeto-
genesis model, it produced a significant decline in
frequencies of cisplatin-induced retching and vomiting
and this is consistent with previous reports in such spe-
cies as dogs [25], rats [80] and Suncus murinus [26]. It is
clear that MPG has some proficiency in scavenging gen-
erated free radicals and that it exerts its beneficial effects
by protecting against oxidative stress [78]. What is more,
our study revealed that MPG is effective when given in
lower doses since in a higher dose MPG itself causes
emesis [25].
Vitamin C is a versatile water soluble antioxidant that
is widely used in complementary oncology [81]. In our
study, it significantly attenuated cisplatin-induced emetic
episodes and this is in accordance with earlier accounts
describing diminished cisplatin emesis in dogs and it
also inhibited kaolin consumption in cisplatin treated
rats [25, 80]. Moreover, at 300 mg/kg, Vit-C produced a
100% reduction of emesis. In relation to such findings,
vitamin C has efficacy in reducing cisplatin oxidative
stress by improving antioxidant levels, repairing DNA
damage and inhibiting lipid peroxidation [82].
We have screened combinations of GP + Vit-C, MPG
+ Vit-C and BM-ButFr + GP against cisplatin-induced
retching and vomiting. Our results showed that the GP
+ Vit-C combination yielded an equivalent inhibition of
emetic episodes to MPG + Vit-C and BM-ButFr + GP.
Additionally, the combinations tended to exert compar-
able, or in some instances marginally improved anti-
emetic effects than either agent given alone. In this
respect, it has been reported that combination of vita-
min E plus vitamin C affords enhanced protection
against emetic episodes in dogs [25]. Similarly, a com-
bination of vitamins C and E provides superior anti-
emetic activity than either of the antioxidants alone in
cisplatin-induced pica behavior in rats [80]. No single
antiemetic is completely effective at blocking emesis in
either phase, but when administered together, the anti-
emetic efficacy of the combination is often greater than
that of each agent given individually [77].
The inherent antioxidant potential of MPG, Vit-C, GP
and BM-ButFr was evaluated by the DPPH free radical
scavenging assay as this method is considered as one of
the standard colorimetric methods for the evaluation of
antioxidant properties of natural and pure compounds
[83]. The antioxidant activity of the tested compounds
was quantified in terms of EC50, antiradical power and
stoichiometry. Agents with a low EC50/stoichiometry
value plus high antiradical power indicated strong antioxi-
dant activity [83, 84]. Consequently, a distinct antioxidant
capability was observed for GP which yielded EC50, anti-
radical power and stoichiometry values of 6.498, 0.1567
and 13.00 respectively, and this was followed in rank order
by BM-ButFr (55.61, 0.0159, 111.2), MPG (67.66, 0.0148,
135.3) and Vit-C (69.42, 0.0143, 138.8). These results indi-
cated that as compared to the standard (BHT), all the
selected antioxidants possessed strong free radical scaven-
ging capacities, as seen in previous studies [43, 85].
The rank order of antioxidant activity in vitro corre-
lated well with in vivo antiemetic activity, GP having
strong antioxidant and antiemetic proclivity among the
selected agents. Several studies have reported that anti-
oxidant properties of various plants or synthetic com-
pounds significantly contribute to their antiemetic
activities [25, 86]. In the current study, the high degree
of correlation between the antioxidant and antiemetic
activities as evidenced by their coefficients of determin-
ation which implied that amelioration of cisplatin eme-
togenesis could at least be partially ascribed to the
potent free radical scavenging capacities of GP, MPG,
BM-ButFr and Vit-C. A substantial body of evidence
suggests that oxidative stress is one of the triggering
mechanisms in the mediation of vomiting induced by
chemotherapeutic agents such as cisplatin [87, 88].
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Cisplatin induces lipid peroxidation in the brain, liver
and small intestine and releases serotonin by generat-
ing free radicals. Antioxidants scavenge the generated
free radicals and protect the enterochromafin cells
from oxidative injury thereby suppressing the release
of serotonin in the emetogenic pathway [26]. Free
radical mediated reactions are responsible for a wide
range of chemotherapy-induced side effects and anti-
oxidants are able to protect non-malignant cells and
organs against some of the damaging effects of cytostatic
agents [63]. Dietary supplementation with synthetic and
herbal antioxidants ameliorates chemotherapy-induced
oxidative stress and diminishes the development of their
side effects as well as improving the overall response to
therapy [89]. Our study therefore endorses the notion that
free radical scavengers may be a beneficial class of prophy-
lactic drugs against cancer chemotherapeutic drug in-
duced emesis. However, further studies are warranted to
investigate if there is direct evidence linking reactive oxy-
gen species with oxidative/redox stress injury by assay of
oxidized lipid or protein markers after cisplatin treatment.
Ultimately, neurochemical analysis should be performed
to further correlate the antiemetic effect of these antioxi-
dants with behavioral parameters in this model of emesis.
Conclusions
Cisplatin treatment was associated with intense vomiting
as exemplified by a significant increase in the number of
emetic bouts, retching, % weight loss and a simultaneous
decrease in the emetic latency in the pigeon model. Pre-
treatment with MPG, Vit-C, GP, and BM-ButFr or their
combinations significantly attenuated cisplatin-induced
elevation of vomiting episodes. The selected agents all
possessed potent free radical scavenging capability and
consequent antioxidant potential as evaluated via the
DPPH free radical scavenging assay. Although all agents
exhibited efficacy, GP was conspicuous with respect to an-
tiemetic and antioxidant potential. Evaluation of correl-
ation coefficients disclosed close linear relationships
between antioxidant and antiemetic propensity emphasiz-
ing the involvement of antioxidant activity in the reduc-
tion of cisplatin-induced retching and vomiting episodes
for all the agents tested in the study.
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